EU regulators decline separate heart failure use for Mounjaro but add SUMMIT data to label

European Union regulators turned down a request to add heart failure with preserved ejection fraction (HFpEF) as a stand-alone approved use for tirzepatide (Mounjaro), saying on January 30, 2026 that the trial evidence will instead be written into the product information that prescribers consult ^[1][3]. The Committee for Medicinal Products for Human Use, which handles these reviews for the European Medicines Agency, declined to recommend the extension the manufacturer sought ^[3].

In HFpEF, the heart wall becomes too stiff to relax and fill between beats, so it pushes out less blood than the body needs. People typically struggle with breathlessness, tiredness and swelling of the ankles and feet ^[1].

Regulators gave the drug credit on two fronts inside that study: fewer hospital stays for heart failure, and better patient-reported quality of life ^[1]. They drew the line at the most serious measure. The medicine did not cut the number of deaths caused by heart and circulatory problems, EMA said ^[1]. The agency also said it could not settle whether the heart failure improvements come from the drug itself or from the weight participants shed, and it pointed out that obesity is known to raise heart failure risk and that losing excess weight can ease HFpEF symptoms in adults with obesity ^[1]. Because adults with obesity are already eligible for the medicine under its weight management approval, EMA concluded a second, condition-specific indication was not needed ^[1].

The supporting trial, called SUMMIT, enrolled 731 adults with class II to IV heart failure, an ejection fraction of at least 50%, and a body mass index of at least 30. They received either tirzepatide up to 15 mg injected under the skin once weekly or a placebo, for 52 weeks or longer ^[3]. A combined measure of cardiovascular death or a worsening heart failure event — hospital admissions, urgent heart failure visits, or a step-up in diuretic treatment, which flushes out excess fluid — occurred in 36 people taking tirzepatide (9.9%) and 56 taking placebo (15.3%). That works out to a hazard ratio of 0.62, with a P value of .026 ^[1][3]. Symptoms and their effect on daily living were scored with a questionnaire called KCCQ-CSS after 52 weeks ^[1].

The most frequently reported side effects are digestive: nausea, vomiting, constipation and diarrhea, usually mild to moderate and more likely after a dose change ^[3]. The manufacturer told EMA that patients currently in clinical trials face no consequences from the decision, and Mounjaro has been authorized in the EU since September 2022 ^[1].

Why it matters for patients

For adults in the EU living with both obesity and HFpEF, access does not disappear with this ruling. That group already falls within the weight management approval, which covers a BMI of 30 or above, or a BMI of 27 to 30 alongside weight-related conditions such as type 2 diabetes, high blood pressure, abnormal blood fats or obstructive sleep apnea ^[1][3]. What changes is the paperwork prescribers see: SUMMIT's results move from the medical literature into the official product information ^[1][3].

Two gaps in the evidence were left open. No survival benefit was shown, and it remains unresolved whether the heart failure results are independent of weight loss ^[1][3]. Nor has it been disclosed whether insurers or national health systems in Europe would cover tirzepatide specifically for HFpEF rather than for obesity. EMA's own framing suggests the weight management route is the one it expects clinicians to use ^[1].

What happens next

EMA said the product information will be updated so health professionals can review current data on the medicine's effects in adults with obesity and chronic HFpEF, but it gave no date for that change ^[1]. No comparable US regulatory step on a heart failure use for tirzepatide has been reported, and no timeline for one has been disclosed.